by MVG Consulting | Apr 22, 2020 | Clinical Trials
As the demand for COVID-19 testing continues to outpace supply, CRISPR emerges with innovative and promising potential to fill that gap. Researchers are racing to develop quick, home-based tests for the virus that could deliver test results in minutes. None do... by MVG Consulting | Apr 16, 2020 | Featured, Industry News
MVG Insights In lieu of the COVID-19 outbreak, the FDA has issued 3 clinical guidances outlining new protocols related to the following: REMS requirements, alcohol-based sanitizer production, and the conduct of clinical trials of medical products. Each guidance... by MVG Consulting | Apr 6, 2020 | Company News, Featured
A look into Risk Evaluation and Mitigation Strategies (REMS) programs and how MVG can help. MVG Insights: REMS Monday, April 6, 2020 Risk Evaluation and Mitigation Strategies (REMS) programs were instituted as part of the FDA Amendments Act (FDAAA) in 2007 to provide...